NASDAQ: ENSCEnsysce Biosciences Inc Stock
$0.25-0.01 (-3.85%)
Updated Jun 12, 2026
ENSC Price
$0.25
Fair Value Price
N/A
Market Cap
$3.69M
52 Week Low
$0.23
52 Week High
$2.75
P/E
-0.08x
P/B
-10.85x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$11.79M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-8.34
Operating Cash Flow
-$10M
Beta
0.98
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ENSC Overview
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ENSC's potential to beat the market
- ENSC doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ENSC
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.56 | A | |
| $53.13 | A | |
| $15.82 | A |
Be the first to know about important ENSC news, forecast changes, insider trades & much more!
ENSC News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ENSC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ENSC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ENSC is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ENSC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ENSC due diligence checks available for Premium users.
Valuation
ENSC fair value
Fair Value of ENSC stock based on Discounted Cash Flow (DCF)
Price
$0.25
Fair Value
$0.16
Overvalued by
59.69%
ENSC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ENSC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.08x
Industry
16.53x
Market
14.15x
ENSC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-10.85x
Industry
4.85x
ENSC's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.6M
Profit Margin
0%
ENSC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$2.2M
Liabilities
$2.8M
Debt to equity
-8.34
ENSC's short-term liabilities ($2.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ENSC's short-term assets ($2.01M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ENSC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ENSC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.5M
Investing
$0.0
Financing
-$63.9k
ENSC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ENSC vs Biotech Stocks
Ensysce Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.